Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 12/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14023485 | 0.98 | PTGES (0.58) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14023530 | 0.94 | PTGES (0.59) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14023493 | 0.94 | PTGES (0.59) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17366623 | 0.90 | PTGES (0.47) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17366639 | 0.85 | MEN1 (0.51) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14023651 | 0.85 | MEN1 (0.51) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10067338 | 0.84 | MEN1 (0.61) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14220769 | 0.83 | MEN1 (0.51) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14023441 | 0.83 | MEN1 (0.51) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13872552 | 0.81 | PTGES (0.61) | PTGESMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692113-B1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| WO-2005047266-A9 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | PTGES 2604/4885MEN1 4554/4885KMT2A 396/4885 |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | AHR, CBR3, AADAC | PTGES 2602/4885MEN1 4554/4885KMT2A 362/4885 |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | PTGES 2604/4885MEN1 4554/4885KMT2A 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.